Cardiovascular, Kidney, and Safety Outcomes With GLP-1 Receptor Agonists Alone and in Combination With SGLT2 Inhibitors in Type 2 Diabetes: A Systematic Review and Meta-Analysis

A meta-analysis found that GLP-1 receptor agonists lower heart and kidney complications in type 2 diabetes to a similar degree whether or not patients are also taking an SGLT2 inhibitor, suggesting the two drug classes work independently and add up.